FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3212823054> ?p ?o ?g. }

• W3212823054 endingPage "1257" @default.
• W3212823054 startingPage "1257" @default.
• W3212823054 abstract "Abstract Introduction Treatment with the BCL-2 inhibitor Venetoclax (VEN) in combination with hypomethylating agents (HMA) or low-dose cytarabine (LDAC) has shown encouraging results in patients with acute myeloid leukemia (AML). In contrast to the FDA, EMA approval for unfit AML patients was given only recently, and VEN combinations have therefore often been used as off-label treatment for relapsed/refractory (r/r) AML patients. We conducted a retrospective study of 73 unfit or r/r AML patients treated with a VEN combination between 2017 and 2021 at two German university hospitals. Methods Data was collected by medical chart review and included genetics, ELN2017 risk classification, previous treatment lines, courses of VEN treatment as well as outcome. All statistical tests were performed with GraphPad Prism. The median time of follow-up was 8.3 months. Results At beginning of VEN treatment, the median age was 73 (20-85) years (Table 1). The majority of patients had a secondary (s) AML [n=34 (47%)] and was assigned to the adverse ELN2017 risk group [n=32 (44%)]. Mutations in isocitrate-dehydrogenase 1/2 genes (IDH1/2) were the most frequent alteration [n=19 (26%)]. Before VEN treatment, a total of n=58 (79%) patients had received prior treatment including intensive chemotherapy [n=36 (49%)] and allogeneic stem cell transplantation (allo-HSCT) [n=26 (36%)]. Twenty-five (34%) patients were treated with &gt;4 cycles HMA or LDAC before VEN initiation. VEN was given as first-line treatment in n=15 (21%) patients and started during the first or second treatment cycle of HMA/LDAC. The initial VEN dosage after ramp-up during cycle 1 was in median 400mg (50-800mg). Patients received VEN in combination with azacytidine [n=34 (47%)], decitabine [n=18 (25%)] or LDAC [n=20 (28%)]. In median, patients had received 3 (1-17) VEN cycles at data cut-off. VEN was initiated after progression on HMA/LDAC treatment (&gt;2 cycles) in n=35 (48%) patients. In most patients VEN was discontinued or dose-adjusted during treatment [cycle 1 n=37 (51%), after cycle 1 n=43 (59%)]. Response assessment was available for n=58 (79%) patients, of which n=18 (25%) achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi), n=24 (33%) a partial remission (PR) or stable disease (SD), and n=16 (22%) were refractory to VEN combination treatment. The overall response rate (ORR) including CR/CRi/PR patients was 47% and not influenced by age or previous treatments including allo-HSCT and HMA pretreatment. Achievement of CR/CRi was significantly better in patients with IDH1/2 and/or NPM1 mutations (Figure 1). The median overall survival (OS) of the entire cohort was 6.5 months. OS was significantly better in patients achieving a CR/CRi (20.3 months) as compared to patients with PR/SD/RD. (p&lt;0.0001; Figure 2 A). OS was shorter in patients with more than two prior treatment lines (p=0.01, Figure 2 B) and in patients who had received allo-HSCT (p=0.05, Figure 2 C). There was no significant impact on OS with respect to age (&gt;=65 years), ELN2017 risk group or previous HMA treatment. OS was however significantly longer in patients harboring NPM1 and/or IDH1/2 mutations (p=0.016; Figure 2 D). Conclusions Our real-world analysis demonstrates that VEN combination treatment is feasible and effective also in r/r AML patients. Response rates and survival were lower than in patients treated with VEN combinations in first line (DiNardo, NEJM 2020) and in our cohort highly influenced by the number of previous treatment lines. As in patients treated with VEN combinations at fist line, the NPM1 and IDH1/2 genotype was associated with better response and survival. Further studies with larger cohorts are needed to investigate the role of VEN combinations in r/r AML. Figure 1 Figure 1. Disclosures Westermann: Abbvie: Consultancy, Honoraria; Astellas: Honoraria; Novartis: Consultancy, Honoraria; BMS: Honoraria; Amgen: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Stem Cell Line: Consultancy, Honoraria. Bullinger: Seattle Genetics: Honoraria; Bayer: Research Funding; Bristol-Myers Squibb: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Astellas: Honoraria; Amgen: Honoraria; Daiichi Sankyo: Consultancy, Honoraria; Gilead: Consultancy; Pfizer: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Jazz Pharmaceuticals: Consultancy, Honoraria, Research Funding; Menarini: Consultancy; Sanofi: Honoraria; Celgene: Consultancy, Honoraria; Hexal: Consultancy. Keller: Abbvie: Other: Advisory Role. Krönke: BMS/Celgene: Other: Advisory board; Abbvie: Other: Advisory board. Goetze: Abbvie: Other: Advisory Board; BMS/Celgene: Other: Advisory Board, Research Funding. OffLabel Disclosure: Venetoclax was used off-lable in unfit and relapsed/refractory AML patients in combination with HMA/LDAC." @default.
• W3212823054 created "2021-11-22" @default.
• W3212823054 creator A5012026477 @default.
• W3212823054 creator A5027030420 @default.
• W3212823054 creator A5028510513 @default.
• W3212823054 creator A5038625369 @default.
• W3212823054 creator A5040956966 @default.
• W3212823054 creator A5050454200 @default.
• W3212823054 creator A5059538708 @default.
• W3212823054 creator A5060702960 @default.
• W3212823054 creator A5060811966 @default.
• W3212823054 creator A5067435729 @default.
• W3212823054 creator A5083170898 @default.
• W3212823054 creator A5085192155 @default.
• W3212823054 date "2021-11-05" @default.
• W3212823054 modified "2023-10-01" @default.
• W3212823054 title "Combination Treatment of Venetoclax and Hypomethylating Agents (HMA) or Low-Dose Cytarabine (LDAC) for Patients with Acute Myeloid Leukemia (AML) - Real-World Data from Two German Academic Centers" @default.
• W3212823054 doi "https://doi.org/10.1182/blood-2021-150943" @default.
• W3212823054 hasPublicationYear "2021" @default.
• W3212823054 type Work @default.
• W3212823054 sameAs 3212823054 @default.
• W3212823054 citedByCount "1" @default.
• W3212823054 countsByYear W32128230542023 @default.
• W3212823054 crossrefType "journal-article" @default.
• W3212823054 hasAuthorship W3212823054A5012026477 @default.
• W3212823054 hasAuthorship W3212823054A5027030420 @default.
• W3212823054 hasAuthorship W3212823054A5028510513 @default.
• W3212823054 hasAuthorship W3212823054A5038625369 @default.
• W3212823054 hasAuthorship W3212823054A5040956966 @default.
• W3212823054 hasAuthorship W3212823054A5050454200 @default.
• W3212823054 hasAuthorship W3212823054A5059538708 @default.
• W3212823054 hasAuthorship W3212823054A5060702960 @default.
• W3212823054 hasAuthorship W3212823054A5060811966 @default.
• W3212823054 hasAuthorship W3212823054A5067435729 @default.
• W3212823054 hasAuthorship W3212823054A5083170898 @default.
• W3212823054 hasAuthorship W3212823054A5085192155 @default.
• W3212823054 hasConcept C104317684 @default.
• W3212823054 hasConcept C126322002 @default.
• W3212823054 hasConcept C141071460 @default.
• W3212823054 hasConcept C143998085 @default.
• W3212823054 hasConcept C150194340 @default.
• W3212823054 hasConcept C185592680 @default.
• W3212823054 hasConcept C190727270 @default.
• W3212823054 hasConcept C2777198975 @default.
• W3212823054 hasConcept C2777938653 @default.
• W3212823054 hasConcept C2778041864 @default.
• W3212823054 hasConcept C2778461978 @default.
• W3212823054 hasConcept C2778729363 @default.
• W3212823054 hasConcept C2779675984 @default.
• W3212823054 hasConcept C2780235182 @default.
• W3212823054 hasConcept C38652104 @default.
• W3212823054 hasConcept C41008148 @default.
• W3212823054 hasConcept C55493867 @default.
• W3212823054 hasConcept C71924100 @default.
• W3212823054 hasConcept C9583187 @default.
• W3212823054 hasConceptScore W3212823054C104317684 @default.
• W3212823054 hasConceptScore W3212823054C126322002 @default.
• W3212823054 hasConceptScore W3212823054C141071460 @default.
• W3212823054 hasConceptScore W3212823054C143998085 @default.
• W3212823054 hasConceptScore W3212823054C150194340 @default.
• W3212823054 hasConceptScore W3212823054C185592680 @default.
• W3212823054 hasConceptScore W3212823054C190727270 @default.
• W3212823054 hasConceptScore W3212823054C2777198975 @default.
• W3212823054 hasConceptScore W3212823054C2777938653 @default.
• W3212823054 hasConceptScore W3212823054C2778041864 @default.
• W3212823054 hasConceptScore W3212823054C2778461978 @default.
• W3212823054 hasConceptScore W3212823054C2778729363 @default.
• W3212823054 hasConceptScore W3212823054C2779675984 @default.
• W3212823054 hasConceptScore W3212823054C2780235182 @default.
• W3212823054 hasConceptScore W3212823054C38652104 @default.
• W3212823054 hasConceptScore W3212823054C41008148 @default.
• W3212823054 hasConceptScore W3212823054C55493867 @default.
• W3212823054 hasConceptScore W3212823054C71924100 @default.
• W3212823054 hasConceptScore W3212823054C9583187 @default.
• W3212823054 hasIssue "Supplement 1" @default.
• W3212823054 hasLocation W32128230541 @default.
• W3212823054 hasOpenAccess W3212823054 @default.
• W3212823054 hasPrimaryLocation W32128230541 @default.
• W3212823054 hasRelatedWork W2091231814 @default.
• W3212823054 hasRelatedWork W2121399127 @default.
• W3212823054 hasRelatedWork W2763210453 @default.
• W3212823054 hasRelatedWork W2906932504 @default.
• W3212823054 hasRelatedWork W3095951328 @default.
• W3212823054 hasRelatedWork W3212823054 @default.
• W3212823054 hasRelatedWork W3217791952 @default.
• W3212823054 hasRelatedWork W4205445180 @default.
• W3212823054 hasRelatedWork W4206245401 @default.
• W3212823054 hasRelatedWork W4224925603 @default.
• W3212823054 hasVolume "138" @default.
• W3212823054 isParatext "false" @default.
• W3212823054 isRetracted "false" @default.
• W3212823054 magId "3212823054" @default.
• W3212823054 workType "article" @default.